I agree with all points made.

growacet - Right now I see Hepa as the obvious answer. This scares me because of the low prices that Hepa has paid all along. But I think Don is boxed in a corner. Hope I'm wrong.

golf - It was the "efficacy" implication I was trying to flush out. From what I undersatnd if a compound has good enough safety at an FA stage but if there is marginal evidence that the drug is having minimal +ve effect on the desease then the drug company can decide not to invest more money in the trial because the stats suggest it may have only a marginal impact OR they can continue to invest and possibly increase sample size in order to achieve statistical significance (even through they may or may not achieve clinical or functional significance). So if your interpretation is correct I agree that it is fantastic news which RVX failed to highlight.

Hart - I agree on public offering. Don almost seems to have a distain for the public markets. Who knows why but the broader held the shares are the higher the probability that Don could lose control at a low price.

He's got something up his sleeve I hope and I hope it is good. Perhpas if he is protecting his own interests it will protect ours?

GLTA

Toinv